Kidney function declines over time and therefore periodic monitoring should be performed to assess whether anticoagulant dose modifications may be warranted. Direct oral anticoagulants (DOACs) are noninferior to warfarin among patients with CKD; however, no direct comparisons have been performed to provide sufficient evidence to recommend one particular DOAC over another. The DOAC safety profiles appear to be superior to warfarin, reducing the risk for intracranial hemorrhage. Annual reevaluation of treatment goals with discussion of the benefits and harms of continued anticoagulation therapy should be performed.
Learn more about managing patients with CKD.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Sandeep K. Goyal. Fast Five Quiz: Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation - Medscape - Mar 08, 2022.